Semaglutide Peptide Calculator

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with a plasma half-life of approximately 7 days—the longest among approved GLP-1 analogues. It was engineered from native GLP-1(7-37) through two key structural modifications: an amino acid substitution at position 8 (Aib for Ala) that confers near-complete resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and conjugation of a C18 fatty diacid moiety via a hydrophilic linker to the lysine residue at position 26. This fatty acid chain enables high-affinity, non-covalent binding to serum albumin, dramatically reducing renal clearance and extending circulating half-life.

In research preparations, semaglutide is available as a lyophilized powder in vials of 2mg and 5mg—the two most common formats used in preclinical dosing studies. Its molecular weight is approximately 4,113.6 Da, placing it in the larger range of therapeutic peptides. This molecular size contributes to its favorable albumin-binding pharmacokinetics but requires careful reconstitution technique to avoid aggregation.

The Incretin System and GLP-1 Receptor Signaling

Semaglutide exerts its primary effects by binding to and activating the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR) expressed in the pancreas, gastrointestinal tract, heart, kidney, and central nervous system. Under normal physiology, endogenous GLP-1 is secreted by intestinal L-cells in response to nutrient ingestion and acts as an incretin hormone—potentiating glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon release from alpha cells. This glucose-dependency is pharmacologically important: insulin secretion is amplified only when postprandial glucose is elevated, substantially reducing the hypoglycemic risk associated with receptor activation.

Pancreatic Effects: Insulin and Glucagon

At the beta cell, GLP-1R activation by semaglutide triggers adenylyl cyclase, elevating intracellular cAMP levels. This activates protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac2), both of which potentiate glucose-stimulated insulin secretion (GSIS) by enhancing calcium influx through voltage-gated channels and sensitizing the insulin exocytosis machinery. Simultaneously, semaglutide inhibits glucagon secretion from alpha cells via paracrine insulin and somatostatin signaling, reducing hepatic glucose output and suppressing postprandial glucose excursions.

Gastric Emptying and GI Motility

Semaglutide significantly slows gastric emptying by activating GLP-1Rs on vagal afferent neurons and enteric ganglia. This delay in gastric emptying attenuates the rate of nutrient absorption into the bloodstream, blunting postprandial glucose spikes and reducing caloric absorption velocity. In research models, this effect is dose-dependent and contributes to the overall reduction in food intake observed.

Central Nervous System: Hypothalamic Arcuate Nucleus

Beyond peripheral actions, semaglutide crosses the blood-brain barrier—particularly at circumventricular organs where the barrier is fenestrated—and acts directly on GLP-1Rs in the hypothalamic arcuate nucleus (ARC). Within the ARC, GLP-1R activation suppresses orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons while activating anorexigenic pro-opiomelanocortin (POMC) neurons. The net effect is reduced caloric intake through central appetite suppression. Brainstem GLP-1R signaling in the nucleus tractus solitarius (NTS) also integrates satiety signals from vagal afferents, further reducing meal size in rodent behavioral studies.

Standard Research Vial Sizes

Research-grade semaglutide is most commonly supplied in 2mg and 5mg lyophilized vials. The 5mg vial is the workhorse for multi-week titration studies due to its larger total peptide mass, which allows for lower-concentration preparations that minimize dosing error on standard insulin syringes.

Step-by-Step Reconstitution Math

The semaglutide calculator uses the following formula to determine concentration and draw volume:

Why Semaglutide Must Not Be Shaken

The C18 fatty diacid side chain responsible for semaglutide's extended half-life also makes it uniquely susceptible to physical agitation-induced aggregation. Mechanical shaking introduces air-liquid interfaces that expose hydrophobic fatty acid domains, promoting inter-molecular association and irreversible fibril formation. Even brief vortexing can result in visible foaming and loss of active peptide. Always reconstitute by injecting BAC water slowly down the vial wall and mixing by gentle rolling between the palms only. If foaming is observed, allow the vial to rest undisturbed for 5 minutes before proceeding.

The standard preclinical research approach for semaglutide dosing follows a conservative titration schedule to characterize tolerability before escalating to higher dose ranges. This mirrors the clinical pharmacology rationale behind approved dosing protocols and is essential for interpretable dose-response data.

Starting Dose: 250mcg (0.25mg)

A 250mcg (0.25mg) starting dose is used in research titration protocols to establish baseline tolerability—particularly for GI-related effects including nausea, reduced intake, and motility changes that are characteristic of GLP-1R agonism. In rodent models, the initial dose period (typically 4 weeks) allows researchers to observe baseline pharmacodynamics before introducing confounding dose-escalation variables. At 25 mcg/unit (5mg vial + 2ml BAC water), the 250mcg dose corresponds to exactly 10 units—a clean, low-error draw on any standard insulin syringe.

• 5mg vial + 2ml BAC water: 25 mcg/unit → 250mcg = 10 units
• 5mg vial + 1ml BAC water: 50 mcg/unit → 250mcg = 5 units
• 2mg vial + 2ml BAC water: 10 mcg/unit → 250mcg = 25 units
• Use the Semaglutide calculator above to generate exact values for any custom vial and BAC water combination.

Dose Escalation Considerations

After establishing baseline response at 250mcg, research protocols typically escalate to 500mcg (0.5mg) for a defined interval before proceeding to higher doses. Each escalation step should be treated as a distinct experimental phase with independent outcome measurements, given semaglutide's 7-day half-life and the extended time required to reach pharmacokinetic steady state (approximately 4–5 half-lives, or 4–5 weeks). Researchers must account for this accumulation window when designing washout periods or cross-over study designs.

Semaglutide is among the more thermally sensitive research peptides due to the combination of its GLP-1 peptide backbone (susceptible to hydrolysis and oxidation) and its fatty acid side chain (susceptible to oxidation and photo-degradation). Strict adherence to storage conditions is required to maintain peptide integrity across a multi-week study.

• Lyophilized (pre-reconstitution): Store at −20°C for long-term (up to 24 months). Stable at 2°C–8°C (36°F–46°F) for up to 6 months. Do not store lyophilized powder at room temperature for extended periods.
• Reconstituted solution: Refrigerate at 2°C–8°C. Use within 28–30 days. Never freeze reconstituted semaglutide—ice crystal formation disrupts albumin-binding conformation and can cause irreversible aggregation.
• Thermal excursions: Even brief exposure above 25°C can accelerate degradation of the fatty acid linker. If a vial has been left at room temperature for more than 2 hours post-reconstitution, potency loss should be assumed and the vial discarded for precision research.
• Light (UV) protection: The fatty diacid moiety undergoes photo-oxidation under UV exposure. Store in amber vials or aluminum foil-wrapped vials at all stages. Minimize bench-top exposure during preparation—work under normal laboratory lighting, not direct UV or high-intensity white light.

What if the semaglutide solution remains cloudy after reconstitution?

A properly reconstituted semaglutide solution should appear clear to slightly opalescent—a very mild opalescence is acceptable due to the amphiphilic nature of the fatty acid conjugate. Persistent cloudiness, visible particulates, or visible foam that does not resolve within 5–10 minutes of rest indicates one of three problems: (1) mechanical agitation during or after reconstitution causing aggregation; (2) thermal shock from injecting cold BAC water into a cold peptide vial—both should be at room temperature before reconstitution; or (3) solvent incompatibility—only bacteriostatic water or sterile saline should be used. A cloudy or particulate-containing vial should be discarded, as aggregated peptide cannot be reliably disaggregated by further mixing and will produce inconsistent dosing data.

How does semaglutide's ~7-day half-life affect research dosing intervals?

Semaglutide's terminal elimination half-life of approximately 165–168 hours (≈7 days) has profound implications for research study design. First, steady-state plasma concentrations are not reached until approximately 4–5 half-lives of consistent dosing—meaning 4 to 5 weeks of weekly administration before pharmacokinetic equilibrium is established. Researchers should not interpret pharmacodynamic effects observed during the first 3–4 weeks as representative of steady-state response. Second, the long half-life necessitates extended washout periods in cross-over or sequential-dose designs: a minimum 5-week washout (5 × 7 days = 35 days) is required to reduce plasma levels below 5% of peak. Third, because steady-state accumulation occurs gradually, the dose-dependent GI effects that are prominent with initial dosing tend to attenuate over time as receptor desensitization and central adaptation occur—a time-course that must be accounted for in tolerability assessments.